UI 015
Alternative Names: UI-015Latest Information Update: 28 May 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antipyretics; Non-opioid analgesics; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Pain in South Korea
- 30 Apr 2020 UI 015 is available for licensing as of 30 Apr 2020. https://www.kup.co.kr/research/innovation_main.htm
- 30 Apr 2020 Korea United Pharm plans to launch UI 015 for Pain in 2021 (Korea United Pharm pipeline, April 2020)